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5 Key Points
•

A systematic literature review identified nine CER methods guidance documents.

•

These documents present more than three hundred individual methods
recommendations, covering topics such as study design, bias, and statistical
analysis.

•

Categories of shared methods recommendations were assembled which
embodies a consensus of recommendations for CER methods.

•

All nine documents recommended transparency and adaptation for relevant
stakeholders in the interpretation and dissemination of results.

•

Other shared recommendations identified in at least seven documents included
transparent operational definitions allowing for replication, assessment of data
and study measure validity, inclusion of clinically meaningful and objectively
measured outcomes, and focusing on gap in knowledge that are relevant for
decision-makers.
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Abstract
Purpose: Due to an increasing demand for quality comparative effectiveness research
(CER), methods guidance documents have been published, such as those from the
Agency for Healthcare Research and Quality (AHRQ) and the Patient-Centered
Outcomes Research Institute (PCORI). Our objective was to identify CER methods
guidance documents and compare them to produce a summary of important
recommendations which could serve as a consensus of CER method recommendations.
Methods: We conducted a systematic literature review to identify CER methods
guidance documents published through 2014. Identified documents were analyzed for
methods guidance recommendations. Individual recommendations were categorized to
determine the degree of overlap.
Results: We identified nine methods guidance documents, which contained a total of
312 recommendations, 97% of which were present in two or more documents. All nine
documents recommended transparency and adaptation for relevant stakeholders in the
interpretation and dissemination of results. Other frequently shared CER methods
recommendations included: study design and operational definitions should be
developed a priori and allow for replication (n=8 documents); focus on areas with gaps in
current clinical knowledge that are relevant to decision-makers (n=7); validity of
measures, instruments, and data should be assessed and discussed (n=7); outcomes,
including benefits and harms, should be clinically meaningful, and objectively measured
(n=7). Assessment for and strategies to minimize bias (n=6 documents), confounding
(n=6), and heterogeneity (n=4) were also commonly shared recommendations between
documents.
Conclusions: We offer a field-consensus guide based on nine CER methods guidance
documents that will aid researchers in designing CER studies and applying CER
methods.
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Introduction
As a result of an ever-increasing number of treatment options, real-world
evidence is needed to inform clinical decision-making. Consequently, the demand for
high-quality comparative effectiveness research (CER) has increased over the past
several years. The Institute of Medicine has defined CER as, “the generation and
synthesis of evidence that compares the benefits and harms of alternative methods to
prevent, diagnose, treat, and monitor a clinical condition or to improve the delivery of
care".1 Inherent in this definition is the head-to-head comparison of treatment
approaches used in clinical practice to provide information on which treatments work
best, for whom, and in which situations. To comparatively evaluate treatments, a wide
range of methods and various study designs, including randomized controlled trials and
observational studies, are utilized.
In response to a number of recent CER funding initiatives based in the United
States, under the 2009 American Recovery and Reinvestment Act and the 2010 Patient
Protection and Affordable Care Act, which established the Patient-Centered Outcomes
Research Institute (PCORI), several methods guidance documents have been
developed recently.2-5 Despite the utility of such guides, it remains unclear which
documents should be followed and under which circumstances, as consensus between
the guidance documents has not been determined. To this end, this review sought to
identify CER methods guidance documents, and then identify areas of agreement
among CER methods recommendations to create a consensus document that may
assist in the design and conduct of high-quality CER, including observational studies and
randomized clinical trials (RCTs).
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Methods
A literature search was conducted in February 2015 by two independent
reviewers (JM, RM) to identify CER methods guides that included specific
methodological recommendations for the design and conduct of CER. To identify
published, peer-reviewed literature, Pubmed's Medical Subject Heading (MeSH) system
and the query “comparative effectiveness research/methods” was used.6 To find
documents that were not published in the peer-reviewed literature, such as industry
reports and white papers, grey literature search methods were employed.7-9 Specifically,
we used the query "comparative effectiveness research" in Google and Google Scholar.
Websites of organizations involved in CER, including the Agency for Healthcare
Research

and

Quality

(AHRQ),

European

Network

of

Centres

for

Pharmacoepidemiology and Pharmacovigilance (ENCePP), PCORI, Food and Drug
Administration, Health Canada, and National Institute for Health, were also searched.
While CER is a newer term to describe an existing discipline that has carried various
names, the focus of our search for methods guidelines was specific to this term that was
popularized by the American Reinvestment and Recovery Act.
A search result title was assessed for relevance to CER methods by the inclusion
of specific words, including "methods," "methodology," "standards," "conducting,"
"guidelines," and "practices". Subsequently, the abstracts from the results with relevant
titles were reviewed. The following information was collected from each abstract:
author(s), year of publication, and affiliations. Each abstract was categorized as a CER
overview, a presentation of specific analytic methods, or a study of a specific therapeutic
topic. Only full-text documents categorized as a CER overview were obtained and
analyzed for potential inclusion as a CER methods guidance document. Any document
not consisting of a set of formal recommendations on CER methods, or those related to
meta-analyses or systematic reviews, were excluded. Guidance documents released as
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part of a series or an update were included together as a single guide. Documents
published through December 2014 were included in our review.
All recommendations regarding CER methods were extracted from each
guidance document by two independent reviewers (JM, RM). The content of each
statement was assessed to determine whether the statement provided guidance for
conducting CER, and therefore should be considered a CER recommendation.
Statements

not

meeting

this

criterion

were

excluded.

The

list

of

included

recommendations were agreed upon by both reviewers and an additional author (AC).

Results
We reviewed 1,819 Pubmed search results and 360 grey literature results, and
identified 248 documents with titles relevant to CER methods. Documents related to a
specific therapeutic area (Pubmed n=32, 19.9%; grey n=7, 8.1%) or a specific
methodology (Pubmed n=64, 39.8%; grey n=34, 39.1%) were excluded, while CER
overviews (Pubmed n=65, 40.4%; grey n=46, 52.9%) were reviewed for inclusion. From
this pool of CER overviews, nine CER methods guidance documents were identified, of
which five were already known to the authors (Figure 1, Table 1). These nine documents
were published between 2009 and 2014. Organizations authored seven of the nine
documents, and individual authors wrote the remaining two.
Following the exclusion of statements not meeting the criterion of a CER
methods recommendation and splitting statements with multiple recommendations into
individual recommendations, there were 312 recommendations. After reviewing all
recommendations, 15 categories of shared recommendations were created by two of the
authors (JM, AC). All recommendations were then reviewed and placed in a
corresponding category or categories, as some recommendations fell in to more than
one category. The number of documents with recommendations in each of the
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categories were totaled. Specific recommendations within categories of shared
recommendations were reviewed in greater detail to identify common themes which
were

also

summed

between

documents.

While

the

categorization

of

the

recommendations was completed by two authors (JM, AC), all of the authors reviewed
and approved these categorizations. Recommendations that did not correspond with any
of the 15 categories were considered non-shared recommendations.
Only one shared recommendation category was identified across all nine CER
documents, suggesting that the interpretation and dissemination of CER study results
should be transparent and adapted for relevant stakeholders (Table 2). Other frequently
shared CER methods recommendations included: study design and operational
definitions developed a priori and transparent enough to allow for replication (n=8
documents, 89%); focus on areas with gaps in current clinical knowledge that are
relevant to decision-makers (n=7, 78%); assess and discuss validity of measures,
instruments, and data, including data collection (n=7, 78%); outcomes, including benefits
and harms, should be clinically meaningful, and objectively measured (n=7, 78%);
appropriateness of exposures and interventions should be assessed and described
(n=6, 67%).
Assessment for and strategies to minimize bias (n=6 documents), confounding
(n=6), and heterogeneity (n=4) were also commonly shared recommendations between
documents. Other shared recommendations supported rigorous literature review to
guide study design and planning (n=6, 67%), use of sensitivity analyses (n=5, 56%),
involving relevant stakeholders (n=5, 56%), use of appropriate statistical techniques
(n=5, 56%), following ethical requirements (n=4, 44%), and improving health care value
(n=2, 22%). There were nine individual non-shared recommendations (3% of all
recommendations) in five of the nine documents which did not fall in to one of the shared
recommendation categories, including protection of the independence of peer review5,
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time and costs considerations as secondary objectives are defined10, and separation of
feasibility studies from the main study results.10

Discussion
This study provides a synthesis of CER methods guidance documents for the
purpose of informing decisions on the development and conduct of quality CER
research. This consensus document identifies the most commonly shared expectations
of quality CER from an interdisciplinary standpoint, incorporating recommendations from
experts in academia, industry, professional societies, and regulatory agencies. Our study
identified nine documents with over 300 recommendations for designing and conducting
CER. We were able to identify the most frequently shared recommendations which can
serve as a summary resource for researchers as they design and implement CER
studies.
The documents had varying approaches to recommending specific CER
methods. For instance, the Patient-Centered Outcomes Research Institute (PCORI),
Agency for Healthcare Research and Quality (AHRQ), and European Network of
Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) present detailed
methodological guidance, organized by topic area, which can serve as a how-to guide
for researchers attempting to design and conduct CER.4, 5, 10 In contrast, the American
Medical Association (AMA) and American Heart Association (AHA) documents provide
less information about study design and analysis and more about health policy, research
dissemination, and general principles to guide researchers.11,

12

Despite their varying

perspectives, the documents are unified in their call for the development of CER
methods standards. By compiling a list of frequently agreed upon CER methods
recommendations, we have facilitated the application of these recommendations for
developing CER research based on expert recommendations.

9

From our list of shared recommendations, it is apparent that some of the most
important aspects of quality CER include adaptation of the interpretation and
dissemination of study results for patients, providers, and payers; interpretation of study
limitation in the context of the population studied; development of a priori study
protocols; evaluation of missing data and measure validity; use of clinically meaningful
endpoints; use of appropriate measures of exposure and statistical techniques, including
sensitivity analyses; assessing and minimizing bias, including misclassification and
immortal time bias, confounding, including residual confounding, and heterogeneity; and
involvement of relevant stakeholders while following ethical requirements. While a study
may adhere to sound CER methodology, the ability to assess the study’s quality is
severely limited if it does not report sufficient amounts of information. The results of our
study support transparency in the protocol and manuscript development process.
Furthermore, transparency in statistical analysis is stressed in CER, allowing for not only
public critique of methodology, but also study reproducibility.
The synthesis of these nine documents demonstrated a large degree of overlap,
as over 97% of individual recommendations were found in at least two documents.
Though the documents themselves were not specifically reviewed for contradictions, no
contradictions were noted in the extracted recommendations. Additionally, while
individual documents may have primary areas of focus for conducting CER, the high
degree of overlap suggests a general sense of agreement among the nine documents
regarding the most important topics. Though a number of these topics are not exclusive
to CER, and may be applied more broadly to pharmacoepidemiology and outcomes
research, the emphasis placed on these recommendations by CER experts highlights
their importance for CER, particularly when considering how CER contributes to clinical
decision-making.13
It should be noted that our consensus guide, summarizing key CER methods
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recommendations, may be useful in the development of detailed, high-quality,
transparent CER that optimizes clinical applicability but does not replace the guidance
provided by the individual documents identified. While the concept of consensus as a
scientific theory has been controversial in the past, our goal was to present a summary
of the overlap between the 312 recommendations from the nine CER methods guidance
documents.14 For specific guidance and additional CER resources, the reader is directed
to the individual documents. Now that a consensus of recommendations has been
identified, it will be important to identify whether consensus exists for how these
recommendations should be implemented and accomplished.
While some recommendations extracted from the guides focus on the reporting
of CER studies, they were interpreted as recommendations for the design and conduct
for CER. For example, while reporting of limitations and confounders is not necessarily
part of conducting research activities, it is an important step in promoting study
transparency. With consistent transparency throughout the study process, study quality
is improved. Furthermore, in the context of design, confounders and limitations should
be considered a priori, so that approaches to minimize confounding and limitations can
be implemented in the design phase.4, 5 One such strategy includes sensitivity analyses,
as “residual confounding should be assessed, and approaches to estimating its effect,
including sensitivity analyses, should be included.” 4, 15 The utility of sensitivity analyses
is also supported by a recent study which identified sensitivity analyses as the single
best predictor of quality for studies published in higher-impact journals.16 The effect of
missing data as a potential limitation must also be assessed thoroughly.4, 15, 17
The goal of this project was to identify areas of agreement among CER methods
recommendations to assist in the design and conduct of high-quality CER. Many of the
recommendations were focused specifically on observational research, rather than
RCTs.

This focus may be a result of the existing clinical trial methods guidance
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documents, including guidance from the Food and Drug Administration on Good Clinical
Practice and Clinical Trials and the Pragmatic-Explanatory Continuum Indicator
Summary (PRECIS). 18, 19 Several other documents that may be useful in the design and
conduct of CER are those specifically focused on reporting of research results, including
the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
Statement, the GRACE Checklist, and the Consolidated Standards of Reporting Trials
(CONSORT) Statement and Checklist.20-22 STROBE and GRACE promote dissemination
of quality observational study results, while CONSORT provides guidance specific to
RCT reporting in order to assess study validity.20-22 While the aforementioned documents
were not included in our analysis as they were either not specific to CER or focused on
reporting rather than the design and conduct of CER, they are important resources,
particularly for the reporting of and assessment of CER quality. Lastly, it is also
necessary to acknowledge international efforts to improve the utilization of effectiveness
research methods in clinical decision-making, including the GetReal project conducted
by the Innovative Medicines Initiative (IMI) and the European Medicines Agency’s (EMA)
Draft guidance for Post-Authorization Efficacy Studies (PAES).23,24
There were several limitations in the development of our consensus document.
Firstly, selection of the documents utilized in our study was based upon specific search
criteria. Thus, while our search returned an expansive list of articles for review, those
documents that did not show up based on our search terminology were not included,
such as the Guidelines for Good Pharmacoepidemiology Practices.25 We used specific
and reproducible criteria for searching the published literature, however, most of the
guidance documents were identified from the grey literature search. Second, it should be
noted that the documents reviewed for consensus were the most up-to-date revisions at
the time the literature search was conducted. As such, guidance documents regularly
updated may have more recent versions, including the ENCePP Guide on
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Methodological Standards in Pharmacoepidemiology (Revision 4).26 Lastly, the
extraction and categorization of shared recommendations was subject to the
interpretation of two independent reviewers. In cases of disagreement regarding the
extraction

or

categorization

of

specific

recommendations

within

a

shared

recommendation category, a third independent reviewer was used for the final
determination. We also mitigated this limitation by having all authors review and approve
the categorization of all recommendations.

Conclusion
We conducted a systematic literature review to develop a single guide of
recommended CER methods, and identified nine CER methods guidance documents.
The shared recommendations identified from this literature review emphasized adequate
and transparent CER study planning and development using validated data, appropriate
exposure measures, clinically meaningful and objectively measured outcomes, and
statistical techniques which minimize bias and confounding. Further, CER should focus
on areas that are relevant for decision-makers and adapt the interpretation and
dissemination of results for key stakeholders. This overview of synthesized guidance
may aid researchers and decision-makers in conducting and implementing quality
comparative effectiveness research.
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Figure 1. Methods guidance document inclusion

Literature search results
reviewed
PubMed (n = 1,819)
Grey Literature (n = 360)
Titles not relevant to CER
methods
PubMed (n = 1,658)
Grey Literature (n = 273)

Titles relevant to CER methods;
full text reviews
PubMed (n = 161)
Grey Literature (n = 87)

Therapeutic Area
PubMed (n = 32)
Grey Literature (n = 7)
Specific Methodology
PubMed (n = 64)
Grey Literature (n = 34)

CER Overviews
PubMed (n = 65)
Grey Literature (n = 46)

Not CER methods guidance
document
PubMed (n = 63)
Grey Literature (n = 38)

CER methods guidance
documents (n = 9)
PubMed (n = 1)
Grey Literature (n = 7)
PubMed & Grey Literature
(n = 1)
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Table 1. CER methods guidance documents
Document
number

1

2

3

4

5

6

7

8

9

Document title

The American Heart
Association's Principles
for Comparative
Effectiveness
12
Research
Good Research
Practices for
Comparative
Effectiveness Research
15, 27, 28
– Parts I,II,III
American Medical
Association Principles
for Comparative
Effectiveness
11
Research
Ten Commandments”
for Conducting
Comparative
Effectiveness Research
Using “Real-World
17
Data
Principles for Planning
and Conducting
Comparative
Effectiveness
29
Research
PCORI Methodology
Standards / PCORI
5
Methodology Report
Developing a Protocol
for Observational
Comparative
Effectiveness
4
Research
Guide on
Methodological
Standards in
Pharmacoepidemiology
10
(Revision 3)
GRACE Principles

21

Authors

Year

Affiliation

Methods
recommendations (N)

Document
source

Gibbons et
al.

2009

AHA

10

Grey
Literature

Berger et
al.
Cox et al.
Johnson et
al.

2009

ISPOR

32

Pubmed,
Grey
Literature

AMA

2011

AMA

11

Grey
Literature

Willke RJ,
Mullins D

2011

Pfizer,
University
of
Maryland

13

Pubmed

Luce et al.

2012

Various

13

Grey
Literature

PCORI

2013

PCORI

31

Grey
Literature

Velentgas
et al.

2013

AHRQ

133

Grey
Literature

ENCePP

2014

ENCePP

43

Grey
Literature

Dreyer et
al.

2014

GRACE

26

Grey
Literature

AHA, American Heart Association; AHRQ, Agency for Healthcare and Research Quality;
AMA, American Medical Association; ENCePP, European Network of Centres for
Pharmacoepidemiology and Pharmacovigilance; GRACE, Good Research for
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Comparative Effectiveness; ISPOR, International Society for Pharmacoeconomics and
Outcomes Research; PCORI, Patient-Centered Outcomes Research Institute
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Table 2. Categories of shared CER methods recommendations

Shared CER Methods Recommendations
Interpretation and dissemination of CER study results should be
transparent and adapted for relevant stakeholders
Interpret results in the context of the population studied
Adapt presentation of results for different stakeholders
Interpret results in the context of limitations
CER study design and operational definitions should be developed a priori
and be transparent to allow for replication
Operational definitions should be included in the study protocol and
deviation from protocol definitions should be described
Present sufficient information to allow for replication
CER should focus on areas with gaps in current clinical knowledge that are
relevant to decision-makers

Document
Numbers*
1-9

1-4, 6-9

N (%)**
9 (100)
5 (56)
4 (44)
2 (22)
8 (89)
5 (56)

1, 3-8

2 (22)
7 (78)

Validity of measures, instruments, and data, including data collection
methods, should be assessed and discussed
Evaluate data validity
Evaluate missing data
Outcomes, including benefits and harms, should be clinically meaningful,
objectively measured, and transparently reported
Outcomes should be clinically meaningful
Outcomes should be objectively measured
Outcomes should be patient-centered

2, 4-9

7 (78)

1, 4-9

5 (56)
4 (44)
7 (78)

Exposures and interventions should be adequately described and
assessed for appropriateness
Incident user design should be utilized if possible

2, 5-9

Assess for and implement strategies to minimize bias

4 (44)
2 (22)
2 (22)

2 (22)
2, 4-5, 7-9

Minimize misclassification bias
Studies should be free of immortal time bias
Assess for and implement strategies to mitigate confounding
Assess for unmeasured, missing, or residual confounders

6 (67)

6 (67)
4 (44)
3 (33)

2, 4, 6-9

6 (67)
4 (44)

Rigorous review of the literature should be performed to guide CER study
design and planning
Review all relevant treatment approaches, including new treatments

1-3, 5, 7-8

6 (67)

Consider sensitivity analyses, including changes in the exposure,
outcome, confounder, or covariate definitions or classifications
Relevant stakeholders should be involved in the planning and conduct of
CER
Utilize appropriate statistical techniques, defined a priori in a statistical
analysis plan, according to study design and endpoints
Develop a comprehensive statistical analysis plan prior to study initiation
Present statistical assumptions
Describe the statistical modelling approach

2, 6-9

5 (56)

3, 5-8

5 (56)

2, 4, 6-8

5 (56)

CER should follow ethical requirements and conflicts of interest should be
fully disclosed
Assess for and report heterogeneity
CER should focus on improving health care value
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4 (44)

3 (33)
3 (33)
3 (33)
3-4, 7-8

4 (44)

4, 6-8

4 (44)

1, 3

2 (22)

*Column values correspond to document number in Table 1.
** N (%) of guidance documents which include the specific recommendation.
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